<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; areas</title>
	<atom:link href="http://www.tapanray.in/tag/areas/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Still Evolving: Pharma’s New Pathway For Digital And F2F Customer Engagement</title>
		<link>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement</link>
		<comments>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/#comments</comments>
		<pubDate>Mon, 15 Feb 2021 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[areas]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Customer-Engagement]]></category>
		<category><![CDATA[Digital F2F]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Evolving. Pharma]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[inbound]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interactions]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[outbound]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[preference]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[uncertain]]></category>
		<category><![CDATA[visits]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10415</guid>
		<description><![CDATA[Last year &#8211; probably left with no better choice &#8211; the pharma industry, in general, had to take an unprecedented interest in digitalization of business processes. It happened faster than ever, especially in the marketing domain, along with a few &#8230; <a href="http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India as a global pharmaceutical outsourcing hub: Some key advantages and the areas of improvement.</title>
		<link>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement</link>
		<comments>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/#comments</comments>
		<pubDate>Mon, 04 Jan 2010 00:30:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[advantages]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[areas]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[hub]]></category>
		<category><![CDATA[improvement]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Some]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=488</guid>
		<description><![CDATA[All over the world, pharmaceutical research and development pipelines are gradually getting dried up. Lesser and lesser blockbuster drugs are now coming up from the ‘mind to the market’. Currently the average annual turnover of over 90% of patented drugs &#8230; <a href="http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-as-a-global-pharmaceutical-outsourcing-hub-some-key-advantages-and-the-areas-of-improvement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
